GLP-1 raises Ozempic retinopathy… Reconfirmed in large-scale analysis
The side effect issue of diabetic retinopathy (DR) of type 2 diabetes treatment glucagon-like peptide-1 receptor agonist (GLP-1 RA) has been reconfirmed. At the time of the development of semaglutide, an increase in retinopathy patients was observed in clinical trials, but as a similar trend was found in a meta-analysis involving a total of 60,000 … Read more